loading
Precedente Chiudi:
$9.09
Aprire:
$9.09
Volume 24 ore:
45,521
Relative Volume:
0.39
Capitalizzazione di mercato:
$129.91M
Reddito:
$166.88M
Utile/perdita netta:
$-74.18M
Rapporto P/E:
-1.7811
EPS:
-5.07
Flusso di cassa netto:
$1.14M
1 W Prestazione:
-4.39%
1M Prestazione:
+4.12%
6M Prestazione:
-33.14%
1 anno Prestazione:
-64.28%
Intervallo 1D:
Value
$9.0025
$9.25
Intervallo di 1 settimana:
Value
$9.00
$9.465
Portata 52W:
Value
$7.8701
$25.43

Anika Therapeutics Inc Stock (ANIK) Company Profile

Name
Nome
Anika Therapeutics Inc
Name
Telefono
(781) 457-9000
Name
Indirizzo
32 WIGGINS AVENUE, BEDFORD, MA
Name
Dipendente
288
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-12
Name
Ultimi documenti SEC
Name
ANIK's Discussions on Twitter

Confronta ANIK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
ANIK
Anika Therapeutics Inc
9.01 131.93M 166.88M -74.18M 1.14M -5.07
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
144.09 63.58B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.91 43.58B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.205 40.83B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
19.80 23.07B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
430.14 19.61B 3.08B 1.24B 1.07B 25.61

Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-17 Iniziato B. Riley Securities Buy
2024-11-01 Reiterato Barrington Research Outperform
2023-08-14 Aggiornamento Barrington Research Mkt Perform → Outperform
2023-03-07 Downgrade Barrington Research Outperform → Mkt Perform
2022-11-09 Aggiornamento Barrington Research Mkt Perform → Outperform
2022-10-14 Ripresa Stephens Equal-Weight
2022-03-09 Downgrade Barrington Research Outperform → Mkt Perform
2022-03-09 Downgrade Stephens Overweight → Equal-Weight
2021-11-16 Iniziato Stephens Overweight
2021-07-16 Iniziato UBS Neutral
2020-12-16 Aggiornamento Barrington Research Mkt Perform → Outperform
2020-05-08 Downgrade Barrington Research Outperform → Mkt Perform
2020-01-21 Aggiornamento Sidoti Neutral → Buy
2020-01-10 Aggiornamento First Analysis Sec Outperform → Strong Buy
2019-11-05 Iniziato BWS Financial Sell
2019-09-24 Reiterato Barrington Research Outperform
2019-09-23 Downgrade First Analysis Sec Strong Buy → Outperform
2019-07-25 Aggiornamento First Analysis Sec Neutral → Strong Buy
2019-02-22 Downgrade First Analysis Sec Outperform → Neutral
2019-02-22 Downgrade Sidoti Buy → Neutral
2018-07-27 Aggiornamento Barrington Research Mkt Perform → Outperform
2018-06-20 Downgrade Barrington Research Outperform → Mkt Perform
2018-06-20 Downgrade First Analysis Sec Overweight → Equal-Weight
2018-05-04 Aggiornamento Barrington Research Mkt Perform → Outperform
2018-02-23 Downgrade Barrington Research Outperform → Mkt Perform
2018-01-24 Aggiornamento First Analysis Sec Equal-Weight → Overweight
2017-10-27 Reiterato Barrington Research Outperform
2016-05-09 Aggiornamento Singular Research BUY - Long-Term → Buy
2016-04-27 Downgrade Northland Capital Outperform → Market Perform
2016-02-26 Reiterato Barrington Research Outperform
Mostra tutto

Anika Therapeutics Inc Borsa (ANIK) Ultime notizie

pulisher
Oct 15, 2025

Multi factor analysis applied to Anika Therapeutics Inc.Weekly Investment Report & Community Verified Swing Trade Signals - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Does Anika Therapeutics Inc. qualify in momentum factor screeningWeekly Volume Report & Weekly High Conviction Ideas - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Why Anika Therapeutics Inc. stock could outperform in 2025Quarterly Trade Summary & Free Verified High Yield Trade Plans - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Is Anika Therapeutics Inc. stock positioned for long term growthQuarterly Portfolio Review & Verified Technical Signals - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

How to escape a deep drawdown in Anika Therapeutics Inc.2025 Valuation Update & Safe Capital Growth Tips - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Best data tools to analyze Anika Therapeutics Inc. stockJuly 2025 Rallies & Fast Exit and Entry Strategy Plans - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

What institutional flow reveals about Anika Therapeutics Inc.2025 Valuation Update & Long Hold Capital Preservation Tips - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Is Anika Therapeutics Inc. (AKP) stock attractive for growth fundsPortfolio Value Summary & Weekly Momentum Stock Picks - newser.com

Oct 14, 2025
pulisher
Oct 13, 2025

Anika Therapeutics Shares Face Mounting Pressure Amid Technical and Legal Woes - AD HOC NEWS

Oct 13, 2025
pulisher
Oct 13, 2025

How to recover losses in Anika Therapeutics Inc. stockJuly 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - newser.com

Oct 13, 2025
pulisher
Oct 10, 2025

Anika Therapeutics Inc. stock trend outlook and recovery path2025 Short Interest & Community Consensus Picks - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire

Oct 09, 2025
pulisher
Oct 09, 2025

United States Adhesion Barrier Market Set for Explosive Growth: - openPR.com

Oct 09, 2025
pulisher
Oct 09, 2025

Can Anika Therapeutics Inc. (AKP) stock sustain double digit ROEJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Weiss Ratings Reiterates "Sell (E+)" Rating for Anika Therapeutics (NASDAQ:ANIK) - MarketBeat

Oct 08, 2025
pulisher
Oct 08, 2025

Orthopedic Digit Implants Market Report 2025-2033, with Profiles of Extremity Medical, Stryker, Zimmer, Smith & Nephew, Depuy, Arthrex, Acumed, Anika Therapeutics, VILEX, and Paragon 28 - Ortho Spine News

Oct 08, 2025
pulisher
Oct 08, 2025

Orthopedic Digit Implants Market Report 2025-2033, with - GlobeNewswire

Oct 08, 2025
pulisher
Oct 05, 2025

What technical models suggest about Anika Therapeutics Inc.’s comebackM&A Rumor & Stock Portfolio Risk Control - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Published on: 2025-10-05 06:33:40 - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Predicting Anika Therapeutics Inc. trend using moving averagesJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Anika Therapeutics Inc. stock trendline breakdownEarnings Recap Report & Fast Gaining Stock Reports - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Trend analysis for Anika Therapeutics Inc. this weekFed Meeting & Risk Managed Investment Entry Signals - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Leading vs lagging indicators on Anika Therapeutics Inc. performanceM&A Rumor & Real-Time Sentiment Analysis - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Analyzing Anika Therapeutics Inc. with multi timeframe chartsMarket Sentiment Report & Community Verified Trade Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Using data filters to optimize entry into Anika Therapeutics Inc.New Guidance & High Conviction Investment Ideas - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Published on: 2025-10-03 01:07:01 - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

How to monitor Anika Therapeutics Inc. with trend dashboardsEarnings Trend Report & High Conviction Investment Ideas - newser.com

Oct 03, 2025
pulisher
Sep 29, 2025

What analysts say about Anika Therapeutics Inc stockMean Reversion Trades & Big Gains Small Investment - earlytimes.in

Sep 29, 2025
pulisher
Sep 29, 2025

Can T I Global Limited Survive Disruption in Its Core IndustryRSI Overbought/Oversold & Double Digit Trading Ideas - earlytimes.in

Sep 29, 2025

Anika Therapeutics Inc Azioni (ANIK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Anika Therapeutics Inc Azioni (ANIK) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Nunes Anne
SVP, Chief Operations Officer
Mar 17 '25
Option Exercise
0.00
3,637
0
21,722
Colleran David
EVP, General Counsel, Corp Sec
Mar 17 '25
Option Exercise
0.00
6,448
0
49,847
Blanchard Cheryl R
President, CEO, Director
Mar 17 '25
Option Exercise
0.00
25,132
0
209,472
Nunes Anne
SVP, Chief Operations Officer
Mar 11 '25
Option Exercise
0.00
2,561
0
18,837
Colleran David
EVP, General Counsel, Corp Sec
Mar 11 '25
Option Exercise
0.00
7,663
0
45,649
Blanchard Cheryl R
President, CEO, Director
Mar 11 '25
Option Exercise
0.00
30,060
0
197,015
Nunes Anne
SVP, Chief Operations Officer
Mar 10 '25
Option Exercise
0.00
3,296
0
17,235
Colleran David
EVP, General Counsel, Corp Sec
Mar 10 '25
Option Exercise
0.00
5,465
0
39,590
Blanchard Cheryl R
President, CEO, Director
Mar 10 '25
Option Exercise
0.00
20,002
0
172,826
$20.39
price down icon 0.56%
$10.05
price up icon 0.75%
drug_manufacturers_specialty_generic RDY
$14.21
price up icon 0.93%
$58.60
price down icon 6.41%
$137.26
price down icon 0.44%
$430.14
price down icon 0.45%
Capitalizzazione:     |  Volume (24 ore):